Alpha Windward LLC bought a new position in shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,440 shares of the medical device company’s stock, valued at approximately $443,000.
A number of other large investors have also modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Tandem Diabetes Care by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 6,227,080 shares of the medical device company’s stock worth $401,771,000 after buying an additional 316,123 shares during the period. BlackRock Inc. increased its position in shares of Tandem Diabetes Care by 2.1% in the second quarter. BlackRock Inc. now owns 4,054,911 shares of the medical device company’s stock worth $261,622,000 after acquiring an additional 83,336 shares in the last quarter. TimesSquare Capital Management LLC increased its position in shares of Tandem Diabetes Care by 9.0% in the third quarter. TimesSquare Capital Management LLC now owns 1,239,535 shares of the medical device company’s stock worth $73,108,000 after acquiring an additional 102,758 shares in the last quarter. FMR LLC raised its holdings in shares of Tandem Diabetes Care by 248.9% during the first quarter. FMR LLC now owns 705,789 shares of the medical device company’s stock valued at $44,818,000 after acquiring an additional 503,482 shares during the period. Finally, Ardevora Asset Management LLP raised its holdings in shares of Tandem Diabetes Care by 14.0% during the third quarter. Ardevora Asset Management LLP now owns 700,836 shares of the medical device company’s stock valued at $41,335,000 after acquiring an additional 86,200 shares during the period. Hedge funds and other institutional investors own 83.16% of the company’s stock.
A number of equities analysts recently commented on the stock. BidaskClub raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, January 10th. Craig Hallum reiterated a “buy” rating and set a $92.00 price objective on shares of Tandem Diabetes Care in a research report on Friday, December 13th. UBS Group raised shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating and set a $75.00 target price on the stock in a research note on Friday, October 4th. Guggenheim started coverage on Tandem Diabetes Care in a report on Thursday, October 17th. They issued a “buy” rating and a $76.00 target price for the company. Finally, ValuEngine cut Tandem Diabetes Care from a “sell” rating to a “strong sell” rating in a research report on Friday, January 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $75.92.
In other Tandem Diabetes Care news, EVP Brian B. Hansen sold 15,000 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $62.01, for a total value of $930,150.00. Following the transaction, the executive vice president now directly owns 17,991 shares of the company’s stock, valued at approximately $1,115,621.91. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Leigh Vosseller sold 10,000 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $70.35, for a total value of $703,500.00. Following the completion of the transaction, the chief financial officer now directly owns 13,265 shares in the company, valued at $933,192.75. The disclosure for this sale can be found here. Insiders have sold a total of 235,462 shares of company stock valued at $14,290,090 in the last three months. Company insiders own 6.90% of the company’s stock.
TNDM stock opened at $67.35 on Wednesday. The firm has a 50 day simple moving average of $62.78 and a 200 day simple moving average of $63.02. Tandem Diabetes Care Inc has a 52 week low of $40.46 and a 52 week high of $74.81. The stock has a market cap of $3.97 billion, a P/E ratio of -26.41 and a beta of 0.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.05 and a current ratio of 2.46.
Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Monday, November 4th. The medical device company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.07. Tandem Diabetes Care had a negative net margin of 7.19% and a negative return on equity of 9.44%. The firm had revenue of $94.66 million for the quarter, compared to analyst estimates of $88.46 million. Sell-side analysts predict that Tandem Diabetes Care Inc will post -0.38 EPS for the current year.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Featured Article: What is the Euro STOXX 50 Index?
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.